Stockscreener 앱 받기
6.77
1.02%
-0.07
시간 외 거래:
6.80
0.03
+0.44%
전일 마감가:
$6.84
열려 있는:
$6.74
하루 거래량:
444.24K
Relative Volume:
0.37
시가총액:
$192.36M
수익:
$157.75M
순이익/손실:
$-29.73M
주가수익비율:
-5.8362
EPS:
-1.16
순현금흐름:
$-21.00M
1주 성능:
+10.44%
1개월 성능:
-9.13%
6개월 성능:
-50.94%
1년 성능:
-64.27%
1일 변동 폭
$6.6258
$6.87
1주일 범위
$6.11
$6.99
52주 변동 폭
$5.85
$24.17
Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile
명칭
Arcturus Therapeutics Holdings Inc
전화
(858) 900-2660
주소
10285 SCIENCE CENTER DRIVE, SAN DIEGO, CA
ARCT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARCT
Arcturus Therapeutics Holdings Inc
|
6.77 | 194.35M | 157.75M | -29.73M | -21.00M | -1.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-24 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-10-23 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-10-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2025-09-04 | 재개 | H.C. Wainwright | Buy |
| 2025-05-28 | 개시 | Scotiabank | Sector Outperform |
| 2025-01-28 | 개시 | BTIG Research | Buy |
| 2024-08-12 | 개시 | Leerink Partners | Outperform |
| 2023-12-13 | 개시 | Canaccord Genuity | Buy |
| 2023-07-24 | 개시 | William Blair | Outperform |
| 2023-05-11 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2022-11-14 | 재개 | Wells Fargo | Overweight |
| 2022-11-10 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2022-11-03 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-11-02 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2022-08-10 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2022-07-19 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-05-11 | 업그레이드 | Robert W. Baird | Underperform → Neutral |
| 2022-04-21 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-01-31 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2021-08-12 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2021-08-11 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-08-10 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2021-07-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-06-25 | 재개 | Goldman | Neutral |
| 2021-06-21 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2021-06-04 | 재개 | Robert W. Baird | Neutral |
| 2021-02-17 | 다운그레이드 | B. Riley Securities | Neutral → Sell |
| 2021-01-19 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2021-01-15 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2021-01-07 | 개시 | Wells Fargo | Overweight |
| 2020-12-29 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2020-12-29 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-12-29 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-12-29 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-12-23 | 다운그레이드 | ROTH Capital | Buy → Sell |
| 2020-12-08 | 재확인 | B. Riley Securities | Buy |
| 2020-12-07 | 재확인 | B. Riley Securities | Buy |
| 2020-10-26 | 개시 | Barclays | Overweight |
| 2020-10-06 | 개시 | Citigroup | Buy |
| 2020-08-26 | 개시 | Piper Sandler | Overweight |
| 2020-07-30 | 재개 | ROTH Capital | Buy |
| 2020-07-16 | 개시 | Raymond James | Outperform |
| 2020-07-13 | 개시 | B. Riley FBR | Buy |
| 2020-06-09 | 다운그레이드 | WBB Securities | Buy → Hold |
| 2020-02-11 | 개시 | Robert W. Baird | Outperform |
| 2020-02-07 | 개시 | Guggenheim | Buy |
| 2020-02-06 | 개시 | Guggenheim | Buy |
| 2019-04-05 | 개시 | H.C. Wainwright | Buy |
| 2018-09-20 | 업그레이드 | WBB Securities | Buy → Strong Buy |
| 2018-01-22 | 개시 | Chardan Capital Markets | Buy |
모두보기
Arcturus Therapeutics Holdings Inc 주식(ARCT)의 최신 뉴스
Arcturus Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - BioSpace
Can Arcturus Therapeutics Holdings Inc. stock rebound after recent weaknessPortfolio Profit Report & Precise Entry and Exit Recommendations - ulpravda.ru
Is Arcturus Therapeutics Holdings Inc. stock positioned well for digital economyJuly 2025 Selloffs & Scalable Portfolio Growth Ideas - ulpravda.ru
mRNA drug developer Arcturus to share its work at major health conference - Stock Titan
Earnings Beat: Can Arcturus Therapeutics Holdings Inc. stock rebound after recent weaknessWeekly Earnings Recap & Real-Time Volume Surge Alerts - ulpravda.ru
Arcturus Therapeutics Holdings (ARCT): Analyst Ratings Suggest a Staggering 415% Upside Potential - DirectorsTalk Interviews
(ARCT) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
UK Regulator OKs Arcturus Therapeutics' COVID-19 Booster Jab - marketscreener.com
What analysts say about Arcturus Therapeutics Holdings Inc stockStraddle and Strangle Trades & Investment Case Studies - earlytimes.in
Arcturus Therapeutics Holdings files for mixed shelf of up to $500 millionSEC filing - MarketScreener
Arcturus Therapeutics Files $500 Million Mixed Shelf - MarketScreener
Precision Trading with Arcturus Therapeutics Holdings Inc. (ARCT) Risk Zones - Stock Traders Daily
Arcturus Therapeutics (ARCT) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Arcturus Therapeutics Holdings Inc.(NasdaqGM:ARCT) dropped from S&P Biotechnology Select Industry Index - marketscreener.com
Will Arcturus Therapeutics Holdings Inc. stock benefit from infrastructure spending2025 Volume Leaders & Risk Controlled Daily Trade Plans - Улправда
How strong is Arcturus Therapeutics Holdings Inc. stock balance sheetMarket Activity Report & Weekly Watchlist of Top Performers - Улправда
How Arcturus Therapeutics Holdings Inc. stock reacts to job market dataTrade Risk Assessment & Weekly High Return Stock Forecasts - Улправда
Why Arcturus Therapeutics Holdings Inc. stock could outperform in 2025Weekly Market Report & Daily Momentum Trading Reports - DonanımHaber
How supply chain issues affect Arcturus Therapeutics Holdings Inc. stockWeekly Trend Recap & AI Enhanced Market Trend Forecasts - DonanımHaber
Arcturus Therapeutics Holdings Inc. Announces Management Changes - marketscreener.com
Arcturus Therapeutics CFO Andy Sassine to leave company - marketscreener.com
Arcturus Therapeutics announces CFO transition and interim appointment By Investing.com - Investing.com Australia
Arcturus Therapeutics Announces CFO Departure and Replacement - TipRanks
Arcturus Therapeutics announces CFO departure and replacement - MSN
Arcturus Therapeutics announces CFO transition and interim appointment - Investing.com
Arcturus Therapeutics Announces CFO Departure and Interim Appointment - TradingView — Track All Markets
Arcturus Therapeutics (NASDAQ:ARCT) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Institution Moves: How buyback programs support Comerica Incorporated Depositary Shares each stockJuly 2025 Spike Watch & Daily Technical Stock Forecast Reports - moha.gov.vn
Retail Surge: How interest rate cuts could boost Arcturus Therapeutics Holdings Inc stock 1; waitfor delay '0:0:15' - moha.gov.vn
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Arcturus Therapeutics Holdings Inc earnings missed by $3.55, revenue fell short of estimates - Investing.com Nigeria
ARCT Stock Plunges 59% in Three Months: Here's What You Need to Know - MSN
Can Arcturus Therapeutics Holdings Inc. stock hit analyst price targetsJuly 2025 Outlook & Weekly Top Gainers Alerts - Newser
How Arcturus Therapeutics Holdings Inc. stock trades before earningsJuly 2025 Recap & AI Powered Buy and Sell Recommendations - Newser
(ARCT) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Arcturus Therapeutics (NASDAQ:ARCT) Stock Price Passes Below 200 Day Moving AverageShould You Sell? - MarketBeat
Guidance Update: How Arcturus Therapeutics Holdings Inc. stock reacts to job market dataNew Guidance & Safe Entry Momentum Stock Tips - moha.gov.vn
Wells Fargo Maintains Arcturus Therapeutics Holdings (ARCT) Overweight Recommendation - MSN
Will Arcturus Therapeutics Holdings Inc. stock deliver shareholder valueJobs Report & Weekly Watchlist of Top Performers - BỘ NỘI VỤ
Form 8-KCurrent report - ADVFN
Arcturus Therapeutics (NASDAQ:ARCT) Shares Pass Below 200 Day Moving AverageShould You Sell? - MarketBeat
Arcturus Therapeutics to Attend Upcoming Investor Conference - MarketScreener
User | sweetwaterreporter.comArcturus Therapeutics to Attend Upcoming Investor Conference - FinancialContent
Arcturus Therapeutics Hits 52-Week Low at $6.02 Amid Major Decline - Markets Mojo
Arcturus Therapeutics Hits 52-Week Low at $5.85 Amid Financial Struggles - Markets Mojo
Responsive Playbooks and the ARCT Inflection - Stock Traders Daily
What drives Arcturus Therapeutics Holdings Inc stock priceLow Beta Stocks & Free Trend Following Techniques - earlytimes.in
Is Arcturus Therapeutics Holdings Inc. stock a safe haven assetJuly 2025 Closing Moves & Stepwise Entry and Exit Trade Signals - newser.com
Balyasny Asset Management L.P. Increases Stake in Arcturus Thera - GuruFocus
Is Arcturus Therapeutics Holdings Inc. stock ready for a breakoutJuly 2025 Review & Technical Buy Zone Confirmation - newser.com
Arcturus Therapeutics Holdings Inc (ARCT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.80%
4.56%
자본화:
|
볼륨(24시간):